Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International ...
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational …